Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Precision Biosciences Inc (DTIL)

Precision Biosciences Inc (DTIL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 110,052
  • Shares Outstanding, K 62,176
  • Annual Sales, $ 115,530 K
  • Annual Income, $ -30,600 K
  • 60-Month Beta 1.83
  • Price/Sales 0.78
  • Price/Cash Flow N/A
  • Price/Book 1.27
Trade DTIL with:

Options Overview Details

View History
  • Implied Volatility 177.40% ( -31.00%)
  • Historical Volatility 147.95%
  • IV Percentile 89%
  • IV Rank 24.62%
  • IV High 537.59% on 06/17/22
  • IV Low 59.76% on 11/10/21
  • Put/Call Vol Ratio 0.02
  • Today's Volume 1,276
  • Volume Avg (30-Day) 580
  • Put/Call OI Ratio 0.03
  • Today's Open Interest 8,441
  • Open Int (30-Day) 4,641

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.43
  • Number of Estimates 4
  • High Estimate -0.37
  • Low Estimate -0.48
  • Prior Year 0.36
  • Growth Rate Est. (year over year) -219.44%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.1100 +41.44%
on 06/16/22
2.2100 -28.96%
on 06/08/22
-0.0600 (-3.68%)
since 05/27/22
3-Month
1.1100 +41.44%
on 06/16/22
3.4400 -54.36%
on 04/01/22
-1.5100 (-49.03%)
since 03/28/22
52-Week
1.1100 +41.44%
on 06/16/22
14.3800 -89.08%
on 09/01/21
-10.5700 (-87.07%)
since 06/28/21

Most Recent Stories

More News
Cybin (CYBN) Up on FDA Clearance of IND for CYB003 in MDD

Cybin (CYBN) receives a "may proceed letter" and IND application clearance from the FDA for a phase I/IIa study evaluating CYB003 for potential treatment of major depressive disorder. Shares up.

AGLE : 0.5455 (-6.86%)
LPTX : 1.2300 (-6.82%)
DTIL : 1.5700 (-11.30%)
CYBN : 0.5780 (-6.02%)
Global Pancreatic Cancer Therapeutics & Diagnostics Market Expected To Reach $5.6 Billion By 2027

Palm Beach, FL – June 28, 2022 – FinancialNewsMedia.com News Commentary – Pancreatic cancer therapeutics and diagnostics involve medical procedures used to diagnose pancreatic cancer and subsequent...

ONCY : 0.9925 (-4.57%)
ONC.TO : 1.30 (-4.41%)
EPZM : 1.4800 (unch)
AXSM : 37.96 (+2.51%)
DTIL : 1.5700 (-11.30%)
NRSN : 2.55 (+2.00%)
Global Pancreatic Cancer Therapeutics & Diagnostics Market Expected To Reach $5.6 Billion By 2027

/PRNewswire/ -- Pancreatic cancer therapeutics and diagnostics involve medical procedures used to diagnose pancreatic cancer and subsequent treatment. Factors...

ONC.TO : 1.30 (-4.41%)
ONCY : 0.9925 (-4.57%)
EPZM : 1.4800 (unch)
AXSM : 37.96 (+2.51%)
DTIL : 1.5700 (-11.30%)
NRSN : 2.55 (+2.00%)
Novartis (NVS) Gets Positive CHMP Opinion for Scemblix in CML

The CHMP recommends approval of Novartis' (NVS) Scemblix for treating adult patients with chronic myeloid leukemia. EU also approves label expansion of Cosentyx.

NVS : 84.17 (-1.30%)
NVO : 108.30 (-4.07%)
UTHR : 234.02 (-2.95%)
DTIL : 1.5700 (-11.30%)
AbbVie's (ABBV) Rinvoq Gets CHMP Nod for New Indication

The CHMP recommends approval of AbbVie's (ABBV) Rinvoq for treating adults with active non-radiographic axial spondyloarthritis.

NVO : 108.30 (-4.07%)
UTHR : 234.02 (-2.95%)
ABBV : 152.49 (-0.42%)
DTIL : 1.5700 (-11.30%)
ANI (ANIP) Soars 6.2%: Is Further Upside Left in the Stock?

ANI (ANIP) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

ANIP : 28.96 (-4.04%)
DTIL : 1.5700 (-11.30%)
Precision BioSciences Announces Closing of Underwritten Offering of Common Stock

Precision BioSciences, Inc. (Nasdaq: DTIL) (the “Company”), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced...

DTIL : 1.5700 (-11.30%)
Precision BioSciences Announces Closing of Underwritten Offering of Common Stock

Precision BioSciences, Inc. (Nasdaq: DTIL) (the “Company”), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced...

DTIL : 1.5700 (-11.30%)
uniQure (QURE) Up on Safety Data From Huntington's Disease Study

uniQure (QURE) posts safety and biomarker data from the 10 patients enrolled in the lower-dose cohort of its ongoing phase I/II study evaluating AMT-130 for treating Huntington's disease.

QURE : 18.57 (-0.54%)
AGLE : 0.5455 (-6.86%)
LPTX : 1.2300 (-6.82%)
DTIL : 1.5700 (-11.30%)
Precision BioSciences' (DTIL) Stock Up This Week: Here's Why

Shares of Precision BioSciences (DTIL) are up as the company inks a gene-editing deal with Novartis to develop a potentially curative treatment for disorders like sickle cell disease.

NVS : 84.17 (-1.30%)
AGLE : 0.5455 (-6.86%)
LPTX : 1.2300 (-6.82%)
DTIL : 1.5700 (-11.30%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Precision BioSciences, Inc. operates as a genome editing company and develops therapeutic products primarily in the United States. The company offers ARCUS, a genome editing platform to cure cancers and genetic disorders. Precision BioSciences Inc. is based in Durham, North Carolina.

See More

Key Turning Points

3rd Resistance Point 2.0900
2nd Resistance Point 1.9700
1st Resistance Point 1.7700
Last Price 1.5700
1st Support Level 1.4500
2nd Support Level 1.3300
3rd Support Level 1.1300

See More

52-Week High 14.3800
Fibonacci 61.8% 9.3109
Fibonacci 50% 7.7450
Fibonacci 38.2% 6.1791
Last Price 1.5700
52-Week Low 1.1100

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar